Dopamine D2/3 occupancy of ziprasidone across a day: A within-subject PET study

Takefumi Suzuki, Ariel Graff-Guerrero, Hiroyuki Uchida, Gary Remington, Fernando Caravaggio, Carol Borlido, Bruce Pollock, Benoit Mulsant, Vincenzo Deluca, Zahinoor Ismail, David Mamo

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Rationale: Ziprasidone is an atypical antipsychotic recommended to be administered twice daily. Objectives: The purpose of this study was to investigate whether occupancy of the dopamine D2/3 receptors by ziprasidone is maintained across a day employing a within subject design. Methods: Positron emission tomography (PET) scans with [11C]- raclopride were performed in 12 patients with schizophrenia while treated with ziprasidone 60 mg twice daily. Each patient completed [11C]- raclopride PET scans at 5, 13 and 23 h after the last dose of ziprasidone. Dopamine D2/3 receptor occupancy was estimated with reference to binding potential data of 44 age- and sex-matched control subjects in the caudate, putamen and ventral striatum. Results: Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively. The time-course of receptor occupancy across the regions indicated an occupancy half-life of 8.3 h. The serum level of ziprasidone associated with 50 % D2/3 receptors occupancy was estimated to be 204 nmol/L (84 ng/ml). Prolactin levels were highest at 5-h post-dose and none showed hyperprolactinemia at 23-h scans. Conclusions: The absence of ziprasidone striatal D2/3 receptor binding 23 h after taking 60 mg under steady-state conditions is consistent with its peripheral half-life. The results support our earlier report that ziprasidone 60 mg administered twice daily appears to be the minimal dose expected to achieve therapeutic central dopamine D2/3 receptor occupancy (i.e. 60 %). Clinical Trials Registration: 24-Hour Time Course of Striatal Dopamine D 2 Receptor Occupancy of Ziprasidone: A PET Study, www.clinicaltrials.gov/ct2/show/NCT00818298, NCT00818298

Original languageEnglish
Pages (from-to)43-51
Number of pages9
JournalPsychopharmacology
Volume228
Issue number1
DOIs
Publication statusPublished - 2013 Jul 1

Keywords

  • C-raclopride
  • Dopamine D receptor
  • Pharmacokinetics
  • Positron Emission Tomography
  • Schizophrenia
  • Ziprasidone

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Dopamine D<sub>2/3</sub> occupancy of ziprasidone across a day: A within-subject PET study'. Together they form a unique fingerprint.

  • Cite this

    Suzuki, T., Graff-Guerrero, A., Uchida, H., Remington, G., Caravaggio, F., Borlido, C., Pollock, B., Mulsant, B., Deluca, V., Ismail, Z., & Mamo, D. (2013). Dopamine D2/3 occupancy of ziprasidone across a day: A within-subject PET study. Psychopharmacology, 228(1), 43-51. https://doi.org/10.1007/s00213-013-3012-1